Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karakousis, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karakousis, C. P.

Annals of Surgical Oncology, Vol 5, Issue 6 473-482, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Therapeutic node dissections in malignant melanoma

C. P. Karakousis
Department of Surgery, State University of New York at Buffalo, Millard Fillmore Health System, 14209, USA.

BACKGROUND: Therapeutic lymphadenectomies involve the dissection and removal of clinically enlarged, histologically positive nodes at the regional nodal basin, in the absence of detectable distant disease. METHODS: The literature dealing with therapeutic lymphadenectomies in malignant melanoma was reviewed. RESULTS: The rate of wound complications varies with the particular nodal basin. The 5-year survival varies from 19% to 38%, with an average of 26%. Survival is affected primarily by the number of histologically positive nodes and extracapsular spread, and secondarily by the extent of disease at the various levels of the nodal basin, fixation of the nodes, and, probably, the preceding disease-free interval. Prognostic parameters of the primary lesion, e.g., thickness, ulceration, and location, also may have an effect on survival. The rate of local recurrence at the nodal basin after lymphadenectomy has varied from 0.8% to 52%. Adjuvant therapy with interferon alfa-2b has improved the 5-year disease-free survival from 26% to 37%. CONCLUSIONS: Therapeutic node dissections in melanoma provide an appreciable 5-year survival rate, which is further augmented by adjuvant therapy. Many series report a significant rate of local recurrence at the nodal basin following therapeutic dissection. Complete lymphadenectomy reduces the rate of local failure with its attendant morbidity.


This article has been cited by other articles:


Home page
 Arch SurgHome page
N. Nathansohn, J. Schachter, and H. Gutman
Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection
Arch Surg, December 1, 2005; 140(12): 1172 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
L. Lam, E. Krementz, C. McGinness, and R. Godfrey
Melanoma of the Clavicular Region: Multimodal Treatment
Arch Surg, September 1, 2001; 136(9): 1054 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
I. Pidhorecky, R. J. Lee, G. Proulx, D. R. Kollmorgen, C. Jia, D. L. Driscoll, W. G. Kraybill, and J. F. Gibbs
Risk Factors for Nodal Recurrence After Lymphadenectomy for Melanoma
Ann. Surg. Oncol., March 1, 2001; 8(2): 109 - 115.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society of Surgical Oncology.